Quaternized U50,488H ameliorates hypoxic pulmonary hypertension through PFKFB3/NLRP3 pathway
Introduction Hypoxia-induced pulmonary arterial hypertension (HPH) is a severe life-threatening disorder manifested by persistent elevation in pulmonary artery pressure and progressive right ventricular hypertrophy. Pulmonary inflammation serves as a core pathological driver contributing to pulmonary vasoconstriction and aberrant vascular remodeling during HPH progression. Methods In the present study, we aimed to evaluate the therapeutic efficacy of Q-U50,488H, a newly synthesized quaternized κ-opioid receptor (κ-OR) agonist, against HPH-associated pulmonary inflammation and further elucidate its detailed molecular mechanisms . For in vivo animal experiments, male C57BL/6 mice were were subjected to chronic‐hypoxia‐induced HPH with Q‐U50,488H and/or nor‐BNI intervention. In vitro assays were performed in primary mouse peritoneal macrophages with LPS‐induced inflammatory activation, in the presence or absence of Q‐U50,488H and nor‐BNI. Results Experimental results demonstrated that Q-U50,488H significantly alleviated pulmonary inflammation lesions in HPH mice, accompanied by diminished pulmonary macrophage infiltration, improved pulmonary vascular remodeling, and decreased right ventricular pressure and right ventricular hypertrophy index. Meanwhile, Q-U50,488H effectively inhibited the secretion of pro-inflammatory mediators including interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6). It also blocked the activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome, and suppressed LPS-induced excessive glycolysis in macrophages. Mechanistically, the suppressive effects of Q-U50,488H on NLRP3 inflammasome activation were strictly dependent on κ-OR signaling. As a key rate-limiting glycolytic enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) was confirmed to positively regulate NLRP3 inflammasome activation. Knockdown of PFKFB3 effectively inhibited NLRP3 inflammasome activity, whereas ectopic overexpression of PFKFB3 largely reversed the anti-inflammatory and metabolic regulatory effects of Q-U50,488H. Discussion In summary, Q-U50,488H represses macrophage inflammatory responses and abnormal glycolytic metabolism via regulating the κ-OR/PFKFB3 signaling axis, thereby ameliorating pulmonary inflammation and pathological vascular remodeling in HPH. This work uncovers the promising therapeutic prospect of κ-OR agonists for HPH intervention, and lays a solid mechanistic basis for the development of novel targeted anti-inflammatory strategies against hypoxic pulmonary hypertension.
Authors
- 冯娜
- Juan Li (ORCID: https://orcid.org/0000-0002-6972-0968)
- Liu Ya
- Sihan Kong
- Jianming Pei
- Xiaoming Gu
- Mingchao Liu
- Jun Li
- Jiayuan Liu
- Feng Fu
- Yunjuan Ren
- Shumiao Zhang
- Qiaojuan Wang
- Guofang Lu
Institutions
- National Clinical Research Center for Digestive Diseases (CN)
- Xijing Hospital (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3389/fphar.2026.1822763
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fourth Military Medical University
- Yakult Bio-Science Foundation
- Key Research and Development Projects of Shaanxi Province